LDL Lowering and Heart Attack Risk Reduction
For every 1 mmol/L (38.7 mg/dL) reduction in LDL-C, the relative risk of myocardial infarction decreases by approximately 27%, while the absolute risk reduction depends on baseline cardiovascular risk and initial LDL-C levels.
Relative Risk Reduction
The evidence consistently demonstrates a log-linear relationship between LDL-C lowering and cardiovascular event reduction across multiple guidelines and meta-analyses:
- Nonfatal myocardial infarction specifically: Each 1 mmol/L (38.7 mg/dL) LDL-C reduction produces approximately 27% relative risk reduction 1
- Major coronary events overall: Approximately 24% relative risk reduction per 1 mmol/L LDL-C lowering 1
- All major vascular events: Approximately 22% relative risk reduction per 1 mmol/L LDL-C reduction 1, 2, 1
This relationship holds remarkably consistent across:
- Primary and secondary prevention populations 1
- Baseline LDL-C levels ranging from <77 mg/dL to >135 mg/dL 1
- Different lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) 3
- Patients with and without diabetes 1
Critical nuance: The relative risk reduction remains constant regardless of baseline LDL-C level, but recent evidence suggests the benefits compound over time. At 1 year of treatment, the relative risk reduction is only 12%, increasing to 20% at 3 years, 23% at 5 years, and 29% at 7 years 4. This explains why short-term trials may underestimate the true benefit of lifelong LDL-C lowering.
Absolute Risk Reduction
The absolute risk reduction varies dramatically based on two factors:
- Baseline cardiovascular risk: Higher risk patients derive greater absolute benefit
- Baseline LDL-C level: Higher starting LDL-C allows for greater absolute reduction
For example, in very high-risk patients (post-ACS with multiple risk factors):
- Achieving LDL-C <70 mg/dL results in approximately 17 fewer myocardial infarctions per 1000 patients over 2 years 5
- Triple lipid-lowering therapy (high-intensity statin + ezetimibe + PCSK9 inhibitor) can reduce 5-year event rates from 22.2% to 14.3%, yielding an 8.0% absolute risk reduction 6
In lower-risk primary prevention populations, the absolute benefit is smaller but still clinically meaningful, particularly when LDL-C ≥3.5 mmol/L (135 mg/dL) 2.
Key Clinical Implications
The log-linear relationship means: At any LDL-C level, the same milligram-per-deciliter reduction produces the same relative risk reduction 7. This has profound implications:
- Patients with low baseline LDL-C but high absolute risk (due to other factors) benefit equally in relative terms from LDL-C lowering 7
- There is no threshold below which further LDL-C lowering stops reducing risk 7, 3
- Even achieving LDL-C levels as low as 0.5 mmol/L (21 mg/dL) continues to reduce events without safety concerns 3
Common pitfall: Focusing solely on absolute LDL-C targets (<70 mg/dL or <55 mg/dL) without considering percent reduction from baseline. Recent evidence shows that achieving ≥50% LDL-C reduction from baseline provides independent prognostic benefit beyond absolute targets 8. Patients achieving both <70 mg/dL AND ≥50% reduction have the lowest event rates.